Accounting of Disclosures
Ron Marcum, M.D., M.S., CHPS
Chief Privacy Officer and Information Security Officer
OHSU Information Privacy and Security Office
Thursday Dec. 11, 2014
11:30 a.m. to 12:30 p.m.
Do you do research under a Waiver of HIPAA Authorization or a Decedents Representation? Did you know that if you send/share Protected Health Information (PHI) outside of OHSU, you need to track those disclosures in OHSU’s electronic Accounting of Disclosures system?
Attend this brown bag session to learn about:
- HIPAA’s Accounting of Disclosures requirement
- When you need to track disclosures in a research study
- How to use OHSU’s electronic Accounting of Disclosures system
- Upcoming changes to the Waiver of Authorization and Decedents forms to help ensure compliance with these requirements
Eric Gouaux, Ph.D.
OHSU’s Dr. Eric Gouaux, senior scientist and principal investigator in the Vollum Institute, this week was awarded an honorary doctorate by the University of Copenhagen for research of the molecular principles underpinning the structure and function of chemical synapses. The award was conferred as part of a symposium organized on behalf of the university’s Drug Research Academy. Dr. Gouaux was the symposium’s keynote speaker, presenting on the topic “Atomic architecture and molecular choreography at the chemical synapses of the brain.”
Honorary doctorates—which are a tradition that goes back to the Middle Ages—are awarded to researchers in recognition of their scientific endeavors and are the highest academic accolade that the University of Copenhagen confers. The vast majority of honorary doctorates are conferred on non-Danish scientists who, as visiting teachers or through international research collaboration, have played a significant role in research and researcher training at the University of Copenhagen. Congratulations to Dr. Gouaux!
The Medical Research Foundation of Oregon has announced the recipients of its 2014 awards for scientific leadership and innovation in Oregon. The awards were presented Wednesday, Nov. 12.
Established in 1942, the MRF promotes medical research achievement across the state. In addition to awarding its annual leadership and innovation honors, it administers more than $1 million in annual research funding and early investigator grants that support the work of outstanding investigators at research institutions across the state.
Fay Horak, Ph.D.
The Mentor Award was presented to Fay Horak, Ph.D., professor of neurology in the OHSU School of Medicine, and physical therapist and motor control neurophysiologist in the OHSU Parkinson Center of Oregon. Horak’s research focuses on neurological disorders that affect balance and gait. Horak was recognized for being a coach, collaborator, adviser and advocate who contributed to the success of 47 postdoctoral fellows, including numerous MRF grant recipients. Many of her former trainees now hold faculty positions around the world.
George Bailey, Ph.D.
The Discovery Award was presented posthumously to George Bailey, Ph.D., distinguished professor emeritus in the Department of Environmental and Molecular Toxicology and retired principal investigator at the Linus Pauling Institute at Oregon State University. Bailey helped pioneer the use of rainbow trout in studying carcinogens. His work in cancer chemoprevention has the potential to dramatically limit colon and liver cancer rates in many regions of the world. His research changed the understanding of carcinogens, especially exposures relevant to humans. Bailey died Oct. 20 following a serious illness.
Joshi J. Alumkal, M.D.
The Richard T. Jones New Investigator Award was presented to Joshi J. Alumkal, M.D., associate professor of medicine and molecular and medical genetics in the OHSU School of Medicine, and co-leader of the OHSU Knight Cancer Institute’s Prostate Cancer Research Program. Alumkal is a physician-scientist whose work on developing more effective treatments for advanced prostate cancer patients has had a significant impact in Oregon and beyond. Alumkal’s research is focused on understanding molecular mechanisms by which lethal prostate cancers evolve.
Susan Tolle, M.D.
The 2014 MacLean Center Prize in Clinical Ethics was presented to Susan Tolle, M.D., at the 26th annual Dorothy J. MacLean Fellows Conference in Chicago earlier this month. Tolle, a professor of medicine at OHSU and director of the OHSU Center for Ethics in Health Care, is one of the founders of the Physician Orders for Life-Sustaining Treatment (POLST) movement in Oregon. The MacLean Prize, an award of $50,000, is the largest award in the clinical medical ethics field. Tolle is putting her prize money back into the OHSU’s Center for Ethics in Health Care, which she directs, becoming the first MacLean Center recipient to donate her award money.
The MacLean Center, which pioneered the formal study of clinical medical ethics in the early 1980s, has the world’s largest clinical medical ethics program for health care providers. Read more about Dr. Tolle’s award in The Oregonian.
The Burroughs Wellcome Fund Postdoctoral Enrichment Program provides a total of $60,000 over three years to support the career development activities for underrepresented minority postdoctoral fellows in a degree-granting institution whose training and professional development are guided by mentors committed to helping them advance to stellar careers in biomedical or medical research. The Fund is committed to supporting the next generation of scientists and researchers, thus they have an interest in advancing the careers of underrepresented minority postdoctoral fellows. Generally, up to 10 awards will be granted for enrichment activities annually. This grant is meant to supplement the training of postdocs whose research activities are already supported. It is not a research grant.
Proposals due January 15, 2015.
To be eligible, applicants must have secured a postdoctoral position with funding (including support by the advisor’s existing research grants) at a degree-granting, research-intensive institution in the U.S. or Canada and must begin the postdoctoral position on or by the designated award commencement date. A person with more than 36 months of postdoctoral experience (in a research laboratory) at the time of application or with more than five years from his/her Ph.D. is not eligible for this award. Must devote at least 75% time to research. The program targets postdoctoral fellows with Ph.Ds in the biomedical or medical sciences. Applicants with M.D. degrees who have secured a postdoctoral research appointment beyond clinical fellowship will be considered for this program. Applicants must be underrepresented minorities (i.e. American Indian or Alaska Native, Black or African American, Hispanic, or Native Hawaiian or other Pacific Islander) and must be citizens of the U.S. or Canada.
The IACUC team has been working hard to create a new, remodeled electronic protocol submissions system for animal researchers. This new system will include:
- Simplified protocol form
- Reduced redundancy
- Procedure-focused, selectable standard procedures
This system has been in the works over the past year, and we have made sure to test it at every stage. To date, we have logged more than 300 hours of testing. In preparation for deployment of the system, we have just wrapped up end-to-end testing. This testing simulated the entire IACUC review process in an effort to ensure a quality system at deployment. This testing involved a wide range of stakeholders, including IACUC analysts, researchers, veterinarians, and ancillary users.
We will be transitioning to the new system over a period of three years. This means that the system will run parallel with the existing system for three years. Initial protocols and 3-year renewals will be submitted in the new eIACUC II system. If any PI would like to move their existing protocol to the new system before their 3-year renewal, they can request support from the IACUC office. Protocols transitioned prior to the 3-year renewal date will still need to undergo IACUC review and approval. Currently, we are looking at transitioning protocols expiring in late March and early April of 2015. We will begin the transition in December 2014 by pairing researchers with an analyst who will support this transition.
The IACUC analysts have been preparing and reaching out to the IACUC community all year through the IACUC Outreach Program. They are ready and available to provide support during the transition process.
Visit out website for access, instructions, and detailed FAQs: www.ohsu.edu/iacuc.
The OHSU Technology Transfer & Business Development (TTBD) office is trying to send a clear message: We’ve got some really cool inventions at OHSU, and we’re open for business. Two new articles from the Portland Business Journal have focused on the TTBD office and the importance of commercializing innovations coming out of universities.
Carmen Pfeifer next to her poster (Developing the new generation of dental composites)
The first article titled “OHSU conferences aim to bring together inventors, investors and industry,” discussed the office’s efforts to give investors and industry representatives a look at early-stage collaboration and investment opportunities and to advance OHSU technologies. These events were held earlier this month. The first was the OHSU MedTech Alliance, which gave OHSU inventors the opportunity to give snapshot presentations of the medical technologies they’re developing. The second event was the OHSU Third Annual Startup Symposium. This event discussed a wide array of startup-related topics such as corporate and traditional venture capital, startup models and business incubators at other universities, and things to know before you start a company. Both events attracted more than 150 attendees, with the majority of attendees coming from outside industry partners or startup companies.
The second article released was titled “‘Just pee in a cup’ and other big ideas from OHSU inventors.” This article highlighted several OHSU technologies developed by our staff.
This included inventions from:
- Kim Burchiel, M.D., FACS, CereMod Inc., Deep brain stimulation to treat obesity
- Trevor Levin, Ph.D., Urology Diagnostics, Extracting DNA from a urine sample to detect bladder cancer recurrence
- David Farrell, Ph.D., FAHA, Gamma Therapeutics, Cardiovascular disease risk assessment
- Paul Cordo, Ph.D., AMES Technology, Inc., Stroke rehabilitation system
- Bill Kelly, MBA, ReelDX, Personal clinical videos
For questions about TTBD-related events or to learn more about our office, please contact us at email@example.com or call our main line at 4-8200.
The purpose of the Mary Kay Ash Foundation Innovative/Translational Cancer Research Award is to fund research in ovarian, uterine, breast, or cervical cancer. Translational research is broadly defined as research that will provide a scientific link between laboratory research and the clinic. Ultimately, the Foundation hopes that such research will lead to improvement in diagnosis, prognosis, prevention, or treatment of cancer. The Foundation anticipates funding between ten and fifteen grants.
Internal deadline: December 19, 2014
Sponsor deadline: February 2, 2015
Limited Submission – This opportunity requires internal coordination since OHSU may only submit one application. If you intend to apply, complete a limited submission form before the internal deadline. Applicants must have a faculty appointment and be associated with the School of Medicine. U.S. citizenship not required.
Chris McGowan, president and CEO of the Portland Trail Blazers, is giving the annual Robert G. Gootee/Moda Health Endowed Lecture in leadership and professionalism, titled “What it takes to win: Strategy and leadership.” The lecture is part of OHSU’s Professionalism Week, and is sponsored by the School of Dentistry.
Friday, Nov. 14, 4 p.m.
CLSB, PSU Auditorium
Reception to follow
This lecture is the first fully endowed lectureship in the history of the OHSU School of Dentistry. The focus of the lectureship is on the attributes of civic engagement and high ethical standards. It was established by the ODS (now Moda Health) Board of Directors to honor Robert Gootee’s 10-year anniversary as president in 2008.
McGowan joined the Trail Blazers in 2012 as president and CEO after 16 years working with teams in Los Angeles. Since he began leading the Blazers, McGowan has immersed himself in the community, serving on a number of charitable boards including the Doernbecher Children’s Hospital Foundation and Boys & Girls Clubs of Portland Metro. Please RSVP to firstname.lastname@example.org.
Joe Gray, Ph.D., associate director of translational research for the Knight Cancer Institute and director of the Center for Spatial Systems Biomedicine, will join Knight Cancer Institute researcher Summer Gibbs, Ph.D., assistant professor in the department of biomedical engineering, and Joseph Carroll, Ph.D., director of business development for the Knight Cancer Institute, to discuss how multi-institution, public-private partnerships are being developed and how they are advancing the research of complex biological systems.
Tuesday, Nov. 11
CLSB 3A003A/B Lecture Hall
The lecture is free and open to the public. Learn more about the lecture on Knight News.